SG Americas Securities LLC Grows Stake in Sight Sciences, Inc. (NASDAQ:SGHT)

SG Americas Securities LLC lifted its stake in shares of Sight Sciences, Inc. (NASDAQ:SGHT) by 47.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,622 shares of the company’s stock after purchasing an additional 5,681 shares during the period. SG Americas Securities LLC’s holdings in Sight Sciences were worth $64,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. KCK LTD. purchased a new stake in shares of Sight Sciences during the fourth quarter worth about $15,925,000. Geode Capital Management LLC grew its stake in Sight Sciences by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock valued at $4,941,000 after acquiring an additional 12,709 shares in the last quarter. State Street Corp grew its stake in Sight Sciences by 17.4% during the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after acquiring an additional 95,843 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Sight Sciences by 46.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock valued at $1,310,000 after acquiring an additional 65,767 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. grew its stake in Sight Sciences by 5.4% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock valued at $1,174,000 after acquiring an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SGHT. Piper Sandler reaffirmed a “neutral” rating and set a $5.50 price objective (down previously from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Citigroup dropped their price target on shares of Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. Stifel Nicolaus dropped their price target on shares of Sight Sciences from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, February 6th. Lake Street Capital dropped their price target on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Wednesday, January 15th. Finally, Morgan Stanley dropped their price target on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday, November 11th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.68.

Insiders Place Their Bets

In other Sight Sciences news, CEO Paul Badawi sold 24,819 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $2.92, for a total transaction of $72,471.48. Following the sale, the chief executive officer now directly owns 5,676,331 shares in the company, valued at $16,574,886.52. This represents a 0.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have acquired 15,000 shares of company stock worth $58,232 and have sold 63,014 shares worth $197,295. 28.90% of the stock is owned by company insiders.

Sight Sciences Stock Performance

Shares of SGHT stock opened at $2.74 on Friday. The firm’s 50 day moving average price is $3.24 and its 200-day moving average price is $4.82. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. Sight Sciences, Inc. has a one year low of $2.50 and a one year high of $8.45. The firm has a market cap of $139.08 million, a P/E ratio of -2.69 and a beta of 2.52.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.